Statistics for Safety and Pharmacokinetics of the Antisense Oligonucleotide (ASO) LY2181308 as a Single-Agent or in Combination with Idarubicin and Cytarabine in Patients with Refractory or Relapsed Acute Myeloid Leukemia (AML)
Total visits
| views | |
|---|---|
| Safety and Pharmacokinetics of the Antisense Oligonucleotide (ASO) LY2181308 as a Single-Agent or in Combination with Idarubicin and Cytarabine in Patients with Refractory or Relapsed Acute Myeloid Leukemia (AML) | 4 |
Total visits per month
| views | |
|---|---|
| November 2024 | 0 |
| December 2024 | 0 |
| January 2025 | 0 |
| February 2025 | 0 |
| March 2025 | 0 |
| April 2025 | 0 |
| May 2025 | 4 |
File Visits
| views | |
|---|---|
| Erba2013Safety-AAM.pdf | 2 |
Top country views
| views | |
|---|---|
| United States | 2 |
| India | 1 |
| Mexico | 1 |
Top city views
| views | |
|---|---|
| Franklin | 2 |
| Mexico City | 1 |
| Pune | 1 |